Of those, we found that rs72613567 in HSD17B13 and known risk variants in SERPINA1 (p.Glu366Lys) and HFE (p.Cys282Tyr) exhibited stronger effects on cirrhosis than on NAFLD. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.